Covid-19 roundup: Inovio enlists plasmid manufacturer to replace the one it’s in legal feud with; Cyberattacks spotted targeting vaccine distribution  –


With its Phase II trial finally underway, Inovio has enlisted another key manufacturing partner to hit its goal of hundreds of millions of doses of its DNA vaccine — if it manages to force its old contract manufacturer into starting tech transfer. Japan’s Kaneka Eurogentec is tasked with plasmid production,

Read the full article at: